Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood pressure experiment in sepsis halted early – kidney protection still unclear

NCT ID NCT01473498

First seen May 19, 2026 · Last updated Jun 22, 2026 · Updated 6 times

Summary

This study tested whether raising the blood pressure target from 65 mmHg to 85 mmHg in patients with septic shock could help prevent kidney injury. Researchers used a drug called norepinephrine to adjust blood pressure and monitored kidney function. The trial was stopped early and only included 27 participants, so no firm conclusions can be drawn.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Reanimation Chirurgicale - Hôpital Kremlin Bicêtre

    Le Kremlin-Bicêtre, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

norepinephrine

What this could lead to

If successful, this approach could point toward a personalized way to manage blood pressure in septic shock to reduce kidney damage.

What could go wrong

The trial was terminated early and enrolled only 27 people, so results are very limited. It is unclear if targeting a higher blood pressure is safe or effective.

Conditions

The condition(s) this trial relates to.

acute kidney injury Sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.